A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM).

Trial Profile

A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2014

At a glance

  • Drugs Pancrelipase (Primary)
  • Indications Exocrine pancreatic insufficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top